Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir-Reference-Cited by-同舟云学术

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Published:2018-09-08 Issue:10 Volume:5 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

George Jomy M¹,Kuriakose Safia S²,Dee Nicola²,Stoll Pam¹,Lalani Tahaniyat³,Dewar Robin²,Khan Muhammad A²,Rehman Muhammad T²,Grossman Zehava⁴⁵,Maldarelli Frank⁴,Pau Alice K⁶

Affiliation:

1. Clinical Center, National Institutes of Health, Bethesda, Maryland

2. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland

3. Uniformed Services University of the Health Sciences, Bethesda, Maryland

4. National Cancer Institute, Frederick, Maryland

5. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

6. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Abstract

Abstract HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/5/10/ofy221/33577037/ofy221.pdf

Reference16 articles.

1. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome;Abram;PLoS One,2017

2. Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients;Naeger;Antivir Ther,2016